Physician profile
Jaya Kala
NPI 1306158878
$82,679.65
in general payments reported to CMS, 2019-2025
8 companies · $23K in 2025
The $23K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $5,400 · 2022: $9,655 · 2023: $11K · 2024: $16K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Honoraria: $9,625 · Travel and Lodging: $7,441 · Food and Beverage: $1,414 · Education: $10.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,970.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,652.50 |
| Honoraria | $9,625.00 |
| Travel and Lodging | $7,440.71 |
| Food and Beverage | $1,414.25 |
| Education | $10.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Btg International INC. | $62,212.27 | 2019-2025 | Voraxaze |
| Alexion Pharmaceuticals, INC. | $19,941.41 | 2022-2025 | Soliris, Ultomiris |
| Genzyme Corporation | $132.48 | 2023 | |
| Horizon Therapeutics Plc | $121.50 | 2019 | |
| Idorsia Pharmaceuticals US INC | $119.91 | 2025 | Tryvio |
| Amgen INC. | $100.51 | 2025 | Tavneos |
| Travere Therapeutics, INC. | $29.31 | 2025 | |
| Novartis Pharmaceuticals Corporation | $22.26 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaya Kala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.